Association between Serum Fructosamine and Kidney Function in Nondiabetic Individuals without Chronic Kidney Disease

You-Fan Peng*
Wen-Yan Cao
Jian-Mei Zhao
Ling Cao
Zhao-Xia Zhang
Dan Chen
Qiong Zhang*

* These Authors equally contributed to the work

Corresponding Author: Qiong Zhang, e-mail: 373606322@qq.com
Source of support: Departmental sources

Background: Serum fructosamine (SF) has been considered to be an indicator that estimates glycemic control in patients with diabetes mellitus (DM). There is increasing evidence that SF concentration and oxidative stress are significantly elevated in patients with chronic kidney disease (CKD). However, the data about SF and its association with kidney function are lacking in nondiabetic individuals without CKD. We included 1891 nondiabetic individuals who had not been diagnosed with CKD to determine the association between SF and kidney function.

Material/Methods: We conducted a retrospective analysis on the basis of the biochemistry database in nondiabetic individuals without CKD.

Results: When eligible participants were stratified in accordance with SF quartiles, from the bottom to the top quartile of SF, a significant decrease of estimated glomerular filtration rate (GFR) was observed in baseline data. SF concentration was negatively associated with estimated GFR (r=−0.066, P=0.004) in the Pearson correlation analysis. Estimated GFR was associated with SF levels independently of glucose (GLU), total cholesterol (TC), triglyceride (TG), and total protein (TP) in multivariable logistic regression analysis (OR=0.984; CI 95% 0.977–0.991; P<0.001).

Conclusions: We suggest that mild elevation of SF concentration is associated with estimated GFR in nondiabetic individuals without CKD. These findings indicate that SF may underlie CKD in nondiabetic individuals.

MeSH Keywords: Fructosamine • Glomerular Filtration Rate • Renal Insufficiency, Chronic

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/893567
Background

Chronic kidney disease (CKD) is associated with atherosclerosis in patients with diabetes mellitus (DM) and in nondiabetic individuals [1]. Very recently, a strong association of early CKD and body adiposity index (BAI) has been reported in 67 non-diabetic, obese, out-clinic patients, and suggested that BAI was a valuable predictor of early stages of CKD in patients with obesity [2]. It is generally known that several indicators are associated with CKD in the clinical laboratory such as microalbumin, urine protein, and serum creatinine. Naro Ohashi et al. [3] reported a significant correlation between plasma glucagon-like peptide-1 levels and hemoglobin A1C (HbA1c), and found that plasma glucose levels might be improved by alogliptin in patients with steroid-induced hyperglycemia.

Serum fructosamine (SF) is a marker that estimates glycemic control formed via nonenzymatic processes [4], and that it is similar with glycated albumin and reflects glycemic control about 2–3 weeks in patients with DM [5,6]. In clinical practice, SF has been widely used to monitoring glycemic control in patients with DM. Some earlier investigations suggested that SF was a useful indicator for estimating the plasma glucose status in patients with CKD [7], Selvaraj N et al. [8] indicated that SF and oxidative stress were significantly elevated in patients with CKD compared with healthy individuals. However, in the available literature, the data about SF and its association with kidney function lacks data from nondiabetic individuals without CKD. Thus, we included 1891 nondiabetic individuals who had not been diagnosed with CKD to assess the association between SF and kidney function.

Material and Methods

In this cross-sectional study we included 1891 nondiabetic individuals without CKD. Samples were collected in the morning and all subjects had fasted. Individuals with following diseases and/or situations were excluded: DM, serious cardiovascular disease, hypertension, presence of chronic dialysis, presence of kidney or liver dysfunction, malnutrition, hematologic disease, infectious disease, malignant tumor, mental disorders, and vegetarians. We conducted a retrospective analysis on the basis of the biochemistry database in nondiabetic individuals without CKD. Our study used the Modification of Diet in Renal Disease (MDRD) formula adjusted coefficient of the Chinese people to evaluate glomerular filtration rate (GFR) [7]. The abbreviated MDRD formula is defined as: GFR=186x(serum creatinine\(^{-1.154}\)) \times \text{age}^{-0.203} \times 1.233 \times 0.702 \text{ (if female)}. Estimated GFR<60 \text{ ml/min/1.73 m}\(^2\) is considered as outcomes of CKD in this study. The biochemical tests were performed by the Roche 8000 automatic biochemical analyzer, consecutively, the reference range of serum creatinine is 53–115 umol/L in our laboratory.

Statistical analysis

The data were described using means ±SD. SF concentration was stratified by quartiles in the study. The \(\chi^2\) test and one-way ANOVA were used to test the differences of variables, a correlation analysis between SF and GFR was performed using the Pearson correlation. Multivariable logistic regression analysis was also used to assess the potential factors that were potential relevant to SF concentration (1\(^{\text{st}}\) versus 4\(^{\text{th}}\) quartile). The data used SPSS16.0 (SPSS Inc., Chicago, IL, USA) statistical software for statistical analysis. \(P<0.05\) was determined as significant.

Results

In the entire group of participants, there were 1489 males and 402 females, whose mean age was 57 years (range, 18–98 years). Mean values of SF, serum creatinine (Cr), glucose (GLU), total protein (TP), globulin (GLB), albumin (ALB), and estimated GFR were 2.07±0.33 mmol/L, 78.1±15.54 umol/L, 5.47±1.15 mmol/L, 72.1±4.73 g/L, 29.3±4.68 g/L, 42.8±3.21 g/L, and 97.4±22.24 ml/min/1.73 m\(^2\), respectively. The main biochemical characteristics of all participants, stratified by SF quartiles, are presented in Table 1. In the baseline, age, triglyceride (TG), total cholesterol (TC), ALB, GLB, GLU, Cr, and GFR significantly changed across SF categories. From the bottom to the top quartile of SF, we observed that estimated GFR in the top quartiles of SF concentration was lower compared with estimated GFR in the lower SF concentration quartiles (99.5±22.21 ml/min/1.73 m\(^2\) vs. 91.5±21.44 ml/min/1.73 m\(^2\)).

When we used the Pearson correlation to identify the association between SF concentration and estimated GFR, our results showed that SF concentration was inversely correlated with estimated GFR in all participants (\(r=-0.066, P=0.004\), as shown in Figure 1. In multivariable logistic regression after adjustment for sex, age, values of high density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), TC, TG, TP, ALB, GLB, GLU, Cr, and GFR, estimated GFR was still associated with SF concentration and it was independent of GLU, TC, TG, and TP (Table 2).

Discussion

The main finding of this study is that SF concentration is associated with estimated GFR independently of GLU, TC, TG, and TP in nondiabetic individuals without CKD. Decreased kidney function causes a higher incidence and hospital admission rate in heart failure patients [9]. Accumulated data suggest that CKD is a substantial risk factor for patients with endstage renal failure and cardiovascular diseases [10,11]. Coca et al. [12]
indicated that serum Cr levels were graded in association with short-term mortality in hospitalized patients, even mild changes in serum Cr concentration. Earlier investigations clearly showed that oxidative stress and inflammatory factors were links between CKD and cardiovascular complications [13,14]. Very recently, some studies found that methoxy polyethylene glycol-epoetin beta may inhibit oxidative stress through enhancing the antioxidant defense system and reducing reactive oxygen species (ROS) in predialysis patients with CKD [15]. Yimaz MI and Xu G et al. [16,17] reported that estimated GFR was negatively associated with malondialdehyde concentration and positively correlated with ROC activity, and that oxidative stress and inflammation alter GFR when CKD develops, which could indicate that oxidative stress and inflammation in the body cause decreased GFR.

In the present study, we found that estimated GFR is associated with increase of SF concentration in nondiabetic individuals without CKD. Importantly, glycation end-products such as SF were reported to be potent immunomodulatory actions, which is associated with the outcomes of ROS production and inflammation [18]. Several lines of evidence show that dietary factors were links between CKD and cardiovascular complications [13,14]. Very recently, some studies found that methoxy polyethylene glycol-epoetin beta may inhibit oxidative stress through enhancing the antioxidant defense system and reducing reactive oxygen species (ROS) in predialysis patients with CKD [15]. Yimaz MI and Xu G et al. [16,17] reported that estimated GFR was negatively associated with malondialdehyde concentration and positively correlated with ROC activity, and that oxidative stress and inflammation alter GFR when CKD develops, which could indicate that oxidative stress and inflammation in the body cause decreased GFR.

Table 1. Baseline characteristics of the entire participants by SF quartiles (n=1891).

| SF quartiles (mmol/L) | I ≤1.84 | II 1.84–2.00 | III 2.00–2.26 | IV >2.26 | P-values |
|-----------------------|---------|--------------|---------------|----------|----------|
| n=496                 | n=469   | n=464        | n=462         |          |          |
| Gender (male/female)  | 387/109 | 365/104      | 371/93        | 366/96   | 0.835    |
| Age(y)                | 55.2±13.70 | 56.6±14.02    | 57.6±13.27    | 58.7±13.58 | 0.001    |
| High density lipoprotein cholesterol (mmol/L) | 1.3±0.31 | 1.4±0.34 | 1.3±0.33 | 1.3±0.37 | 0.134 |
| Low density lipoprotein cholesterol (mmol/L) | 2.9±0.74 | 3.0±0.77 | 3.1±0.78 | 3.0±0.84 | 0.008 |
| Triglycerides (mmol/L) | 1.6±0.80 | 1.7±1.01 | 1.9±1.13 | 2.4±2.55 | <0.001 |
| Total cholesterol (mmol/L) | 4.6±0.93 | 4.8±1.00 | 4.9±1.03 | 5.0±1.11 | <0.001 |
| Total protein (g/L)    | 71.4±4.46 | 71.8±4.91 | 72.4±4.83 | 72.8±4.61 | <0.001 |
| Albumin (g/L)          | 43.0±3.16 | 42.7±3.06 | 42.6±3.13 | 42.9±3.47 | 0.169 |
| Globulin (g/L)         | 28.4±4.53 | 29.2±4.87 | 29.8±4.51 | 29.9±4.65 | <0.001 |
| Glucose (mmol/L)       | 5.2±0.82 | 5.3±0.89 | 5.5±1.14 | 5.8±0.51 | <0.001 |
| Creatinine (umol/L)    | 77.1±15.81 | 77.0±16.70 | 78.9±14.92 | 79.4±14.51 | 0.027 |
| Glomerular filtration rate (mL/min/1.73 m²) | 99.5±22.21 | 99.8±25.09 | 95.7±19.39 | 91.5±21.44 | <0.001 |

Table 2. Determinants of SF concentration (1st versus 4th quartile) in the participants analyzed by multiple logistic regression analysis.

|              | OR (95% CI)     | p-value |
|--------------|-----------------|---------|
| Glucose (mmol/L) | 1.703 (1.474–1.967) | <0.001 |
| Total cholesterol (mmol/L) | 2.983 (2.096–4.254) | <0.001 |
| Triglycerides (mmol/L) | 1.245 (1.080–1.435) | 0.002 |
| Total protein (g/L) | 1.056 (1.022–1.090) | 0.001 |
| Glomerular filtration rate (mL/min/1.73 m²) | 0.984 (0.977–0.991) | <0.001 |

Figure 1. Scatter plot presents a negative correlation between SF and estimated GFR.
antioxidants are able to reduce tissue glycation and that anti-
oxidants play a vital role in preventing protein glycation [19,20],
a finding from the study of Vlassopoulos et al. [21] indicat-
ing that various factors causing inflammation such as infec-
tion or smoking and oxidative stress can promote production
of subsequent glycation. SF is a glycation end-product that is
cumulated through the process of glycation in nondiabetic individ-
uals, and that tissue damage and function loss, through pro-
tein glycation, may occur in the pathogenesis of all kinds of
chronic diseases, including CKD [23]. Obviously, the above re-

tests support that oxidative stress and inflammatory factors
can help explain the association between increased SF concen-
tration and reduced GFR in nondiabetic individuals with-
out CKD. However, further research needs to clarify the mecha-

nism between SF and reduced kidney function in nondiabetic individuals without CKD.

References:

1. Sarnak MJ, Levey AS, Schoolwerth AC et al: Kidney disease as a risk factor
for development of cardiovascular disease: a statement from the American
heart association councils on kidney in cardiovascular disease, high blood
pressure research, clinical cardiology, and epidemiology and prevention.
Circulation, 2003; 108: 2154–69

2. Stepienię M, Stepienię A, Wlazeł RN et al: Obesity indices and adipokines in
non-diabetic obese patients with early stages of chronic kidney disease.
Med Sci Monit, 2013; 19: 1063–72

3. Ohashi N, Tsuji N, Naito Y et al: Alogliptin improves steroid-induced hyper-
glycemia in treatment-naïve Japanese patients with chronic kidney disease
by decrease of plasma glucagon levels. Med Sci Monit, 2014; 20: 587–93

4. Armbruster DA: Fructosamine: structure, analysis, and clinical usefulness.
Clin Chem, 1987; 33: 2153–63

5. Winocour PH, Bhattachar  D, Kalisi P et al: A comparison of direct measures of
glycemia and glyced blood proteins in insulin-dependent diabetes mellitus.
Clin Bioch, 1989; 22: 457–61

6. Schleicher E, Mayer R, Wagner E, Gerbitz K: Is serum fructosamine assay
specific for determination of glycated serum protein? Clin Chem, 1988; 34:
320–23

7. Vos FE, Schollum J, Coulter CV et al: Assessment of markers of glycaemic
control in diabetic patients with chronic kidney disease using continuous

8. Selvaraj N, Bobby Z, Das AK et al: An evaluation of level of oxidative stress
and protein glycation in nondiabetic undialyzed chronic renal failure pa-
cients. Clin Chim Acta, 2002; 324: 45–50

9. Dammann K, Navis G, Voors AA et al: Worsening renal function and progno-
sis in heart failure: systematic review and meta-analysis. J Card Fail, 2007;
13: 599–608

10. Go AS, Chertow GM, Fan D et al: Chronic kidney disease and the risks of death,
cardiovascular events, and hospitalization. N Engl J Med, 2004; 351: 1296–305

11. Anavekar NS, McMurray JJ, Velazquez EJ et al: Relation between renal dys-
function and cardiovascular outcomes after myocardial infarction. N Engl
J Med, 2004; 351: 1283–93

12. Coca SG, Peixoto AJ, Garg AX et al: The prognostic importance of a small
acute decrement in kidney function in hospitalized patients: a systematic
review and meta-analysis. Am J Kidney Dis, 2007; 50: 712–20

13. Cachoferio V, Goicoechea M, Vinueza SG et al: Oxidative stress and inflam-
mation, a link between chronic kidney disease and cardiovascular disease.
Kidney Int, 2008; 111: 54–59

14. Del Vecchio L, Locatelli F, Carini M: What we know about oxidative stress
in patients with chronic kidney disease on dialysis-clinical effects, potential
treatment and prevention. Sem Dial, 2011; 1: 56–64

15. Bartnicki P, Fijalkowski P, Majczyk M et al: Effect of metoxy polyethylene

glycol-epoetin beta on oxidative stress in predialysis patients with chronic
kidney disease. Med Sci Monit, 2013; 19: 994–99

16. Yimaz MI, Saglam M, Caglar K et al: The determinants of endothelial dys-
function in CKD: oxidative stress and asymmetric dimethylarginine. Am J
Kidney Dis, 2006; 1: 42–50

17. Xu G, Luo K, Liu H et al: The progress of inflammation and oxidative stress
in patients with chronic kidney disease. Ren Fail, 2015; 35: 47–49

18. Veeranna V, Ramesh K, KalaPadwa SK et al: Glycosylated hemoglobin and
prevalent metabolic syndrome in nondiabetic multiethnic U.S. adults. Metab
Syndr Relat Distord, 2011; 9: 361–67

19. Harris CS, Beaulieu LP, Fraser MH et al: Inhibition of advanced glycation
end product formation by medicinal plant extracts correlates with pheno-

toclip metabolites and antioxidant activity. Planta Med, 2011; 77: 196–204

20. Visinon JA, Howard TB: Inhibition of protein glycation and advanced glyca-
dition end products by ascorbic acid and other vitamins and nutrients. J Nutr
Biochem. 1996; 7: 659–63

21. Vlassopoulos A, Lean ME, Comet E: Role of oxidative stress in physiolog-
ica

al albumin glycation: A neglected interaction. Free Rad Biol Med, 2013;
60: 318–24

22. Galkina E, Levy K: Leukocyte recruitment and vascular injury in diabetic ne-

phropathy. J Am Soc Nephrol, 2006; 17: 368–77

23. Selvin E, Steffes MW, Ballantyne CM et al: Racial differences in glycemic
markers: a cross-sectional analysis of community-based data. Ann Intern
Med, 2011; 154: 303–9

Conclusions

Several shortcomings exist in this study. First, as a cross-section-
tal study, ability to establish temporal relation between
elevated SF concentrations and GFR is limited. Additionally,
our samples were measured from a single laboratory, SF val-
ues may be slightly different in the various populations and
regions, and a multicenter study should be considered to de-
termine whether the results are applicable to other races and
regions. Finally, we only used estimated GFR to assess kidney
function rather than more accurate measurements of kidney
function. However, we still suggest that mild elevation of SF
concentration is associated with estimated GFR in nondiabetic
individuals without CKD. These findings indicate that SF may
be useful as a CDK risk indicator in nondiabetic individuals.

Statement

The authors have no financial conflicts of interest.